← Back to Clinical Trials
Recruiting NCT06232226

NCT06232226 Attention Deficit Hyperactivity Disorder

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06232226
Status Recruiting
Phase
Sponsor Nantes University Hospital
Condition Attention Deficit Hyperactivity Disorder
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2024-04-11
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
Patients suffering from the co-occurrence of ADHD and addiction(s)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2024-04-11 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The ADA cohort aims for the systematic and standardized collection of sociodemographic, clinical and neuropsychological data, during 2 visits (inclusion and 12 months), from patients suffering from the co-occurrence of ADHD (Attention Deficit Hyperactivity Disorder) and addiction(s), in addition to the treatment as usual adapted to each situation.

Eligibility Criteria

Inclusion Criteria : * Patients aged over 18 years * For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago * For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed * Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019) * For patients who can actually benefit from MPH: who have not yet started taking MPH * Social security affiliates Exclusion Criteria : * Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible * Presenting difficulties in reading or writing the French language making data collection impossible * Unable to commit to being available for the 2 visits planned as part of the cohort * Under guardianship or legal protection * Patients who have used psychoactive substances within 12 hours prior to their visit

Contact & Investigator

Central Contact

Clémence CABELGUEN, PH

✉ clemence.cabelguen@chu-nantes.fr

📞 33 2 40 84 61 16

Frequently Asked Questions

Who can join the NCT06232226 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Attention Deficit Hyperactivity Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06232226 currently recruiting?

Yes, NCT06232226 is actively recruiting participants. Contact the research team at clemence.cabelguen@chu-nantes.fr for enrollment information.

Where is the NCT06232226 trial being conducted?

This trial is being conducted at Nantes, France, Brest, France, Tours, France.

Who is sponsoring the NCT06232226 clinical trial?

NCT06232226 is sponsored by Nantes University Hospital. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology